**US02209S1033 - Common Stock - Premarket: 43.27 -0.19 (-0.44%)**

Taking everything into account, **MO** scores **5** out of 10 in our fundamental rating. **MO** was compared to 9 industry peers in the **Tobacco** industry. Both the profitability and the financial health of **MO** get a neutral evaluation. Nothing too spectacular is happening here. **MO** is valued correctly, but it does not seem to be growing.

ROA (15.56%) VS Industry: 83% outperformed.

2.03

16.92

Profit Margin (22.92%) VS Industry: 50% outperformed.

2.80

31.36

With a **Price/Earnings Ratio** of **8.98**, the valuation of **MO** can be described as very reasonable.

The **Forward Price/Earnings Ratio** of **8.35** indicates a rather cheap valuation of **MO**.

When comparing the **Enterprise Value to EBITDA** ratio of **MO** to the average industry ratio of 8.14, **MO** is valued more expensive than its industry peers.

Price/Earnings (8.98) VS Industry: 66% outperformed.

15.15

7.11

Enterprise Value/ EBITDA (8.14) VS Industry: 40% outperformed.

12.72

6.96

When comparing the Revenue growth rate of the last 5 years to the growth rate of the upcoming 5 years, we see that the growth is accelerating.

The **Earnings Per Share** has been growing slightly by **4.99%** over the past year.

Measured over the past 5 years, **MO** shows a small growth in **Earnings Per Share**. The EPS has been growing by **7.38%** on average per year.

The **Earnings Per Share** is expected to grow by **7.99%** on average over the next 5 years.

When comparing the EPS growth rate of the last years to the growth rate of the upcoming 5 years, we see that the growth is stable.

The **Revenue** has decreased by **-3.53%** in the past year.

Measured over the past 5 years, **MO** shows a decrease in **Revenue**. The Revenue has been decreasing by **-0.38%** on average per year.

Based on estimates for the next 5 years, **MO** will show a small growth in **Revenue**. The Revenue will grow by **2.35%** on average per year.

Past | Future | ||||||
---|---|---|---|---|---|---|---|

5Y | 3Y | 1Y | 1Y | 2Y | 3Y | 5Y | |

EPS | 7.38% | 4.76% | 4.99% | 7.53% | 6.29% | 5.84% | 7.99% |

Revenue | -0.38% | -0.02% | -3.53% | 1.21% | 1.24% | 0.44% | 2.35% |

An Altman-Z score of **3.98** indicates that **MO** is not in any danger for bankruptcy at the moment.

The Piotroski-F score of **MO** is **9.00**. This is a very strong score and indicates great health and profitability for **MO**.

When comparing the Current Ratio of **MO** to the average industry Current Ratio of **3.17**, **MO** is less able to pay its short term obligations than its industry peers. **88%** of its industry peers have a better Current Ratio.

Compared to an average industry Quick Ratio of 2.28, **MO** is worse placed to pay its short term obligations than its industry peers.

Quick Ratio (0.7) VS Industry: 25% outperformed.

0.36

10.72

Current Ratio (0.84) VS Industry: 12% outperformed.

0.72

10.76

Altman-Z (3.98) VS Industry: 100% outperformed.

1.55

3.98

The dividend of **MO** decreases each year by **-3.38%**.

Dividend Yield (8.07%) VS Industry: 100% outperformed.

1.06

8.07

NYSE:MO (3/23/2023, 8:15:04 PM)**-1.69 (-3.74%) **

Chartmill FA Rating

GICS SectorConsumer Staples

GICS IndustryGroupFood, Beverage & Tobacco

GICS IndustryTobacco

Earnings (Last)02-01 2023-02-01/bmo

Earnings (Next)04-26 2023-04-26/bmo

Inst Owners60.87%

Inst Owner Change1.87%

Ins Owners0.11%

Ins Owner Change8.95%

Market Cap77.60B

Analysts71.54

Price Target50.65 (16.54%)

Dividend

Industry Rank | Sector Rank | ||
---|---|---|---|

Dividend Yield | 8.07% |

Dividend Growth(5Y)-3.38%

DP114.75%

Div Incr Years13

Div Non Decr Years13

Ex-Date03-23 2023-03-23 (0.94)

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)-3.59%

Min EPS beat(2)-4.68%

Max EPS beat(2)-2.49%

EPS beat(4)N/A

Avg EPS beat(4)-2.47%

Min EPS beat(4)-4.68%

Max EPS beat(4)-0.51%

Revenue beat(2)2

Avg Revenue beat(2)14.53%

Min Revenue beat(2)13.81%

Max Revenue beat(2)15.24%

Revenue beat(4)4

Avg Revenue beat(4)15.94%

Min Revenue beat(4)13.81%

Max Revenue beat(4)17.38%

PT rev (1m)0.24%

PT rev (3m)1.89%

EPS NQ rev (1m)0.39%

EPS NQ rev (3m)0.64%

EPS NY rev (1m)0.14%

EPS NY rev (3m)0.14%

Revenue NQ rev (1m)1.67%

Revenue NQ rev (3m)1.46%

Revenue NY rev (1m)-0.21%

Revenue NY rev (3m)-0.21%

Valuation

Industry Rank | Sector Rank | ||
---|---|---|---|

PE | 8.98 | ||

Fwd PE | 8.35 | ||

P/S | 3.09 | ||

P/FCF | 9.64 | ||

P/OCF | 9.4 | ||

P/B | N/A | ||

P/tB | N/A | ||

EV/EBITDA | 8.14 |

EPS(TTM)4.84

EY11.14%

EPS(NY)5.2

Fwd EY11.98%

FCF(TTM)4.51

FCFY10.37%

OCF(TTM)4.62

OCFY10.64%

SpS14.05

BVpS-2.23

TBVpS-12.06

PEG (NY)1.19

PEG (5Y)1.22

Profitability

Industry Rank | Sector Rank | ||
---|---|---|---|

ROA | 15.56% | ||

ROE | N/A | ||

ROIC | 30.43% | ||

ROICexc | 35.47% | ||

ROICexgc | 127.81% | ||

OM | 48.15% | ||

PM | 22.92% | ||

GM | 56.5% |

ROICexgc(3y)92.16%

ROICexcg growth 3Y52.87%

ROICexcg growth 5Y26.24%

ROICexc(3y)30.9%

ROICexc growth 3Y22.33%

ROICexc growth 5Y12.39%

OM growth 3Y4.53%

OM growth 5Y4.79%

PM growth 3YN/A

PM growth 5Y-10.5%

GM growth 3Y3.72%

GM growth 5Y3.76%

F-Score9

Asset Turnover0.68

Health

Industry Rank | Sector Rank | ||
---|---|---|---|

Debt/Equity | N/A | ||

Debt/FCF | 3.31 | ||

Debt/EBITDA | 2.17 | ||

Cap/Depr | 90.71% | ||

Profit Quality | 139.99% | ||

Current Ratio | 0.84 | ||

Quick Ratio | 0.7 | ||

Altman-Z | 3.98 |

F-Score9

WACC6.98%

ROIC/WACC18.31

Cap/Depr(3y)83.28%

Cap/Depr(5y)92.71%

Profit Quality(3y)219.04%

Profit Quality(5y)N/A

Growth

EPS 1Y4.99%

EPS 3Y4.76%

EPS 5Y7.38%

EPS growth Q2Q8.26%

EPS Next Y7.53%

EPS Next 2Y6.29%

EPS Next 3Y5.84%

EPS Next 5Y7.99%

Revenue growth 1Y-3.53%

Revenue growth 3Y-0.02%

Revenue growth 5Y-0.38%

Revenue growth Q2Q-2.3%

Revenue Next Year1.21%

Revenue Next 2Y1.24%

Revenue Next 3Y0.44%

Revenue Next 5Y2.35%

EBIT growth 1Y2.27%

EBIT growth 3Y4.51%

EBIT growth 5Y4.39%

EBIT Next Year5.91%

EBIT Next 3Y3.62%

EBIT Next 5Y5.56%

FCF growth 1Y-2.25%

FCF growth 3Y1.98%

FCF growth 5Y11.36%

OCF growth 1Y-1.77%

OCF growth 3Y1.75%

OCF growth 5Y10.99%

*Find stocks with similar Fundamental rating on the USA*

*Find the competitors with the best fundamentals on the USA*

*Find the competitors with the best valuation on the USA*

*Find the competitors with the best dividend on the USA*